CTLA4 and malignant colon neoplasm: For CRC, patients with non-metastatic dMMR colon cancer receiving around 6 weeks of dual blockade of PD1 and CTLA4 and 8 weeks of dual blockade of PD1 and LAG3, respectively in the NICHE2 and NICHE3 studies, and the pCR rates were 67% (72/107) and 79%, respectively.